PAB
Director Trades
| Date | Director | Value |
|---|
Company News
Patrys releases positive data from deoxymabs study to treat ANCA vasculitis
Patrys (ASX: PAB) has released positive data from pre-clinical studies using deoxymabs PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. The therapeutic antibody development company has previously reported non-clinical results that showed the deoxymabs can suppress the formation of neutrophil extracellular traps (NETs), which are structures comprised of […]
Patrys granted Australian patent for Deoxymab platform with nanoparticles to deliver anti-cancer drugs
Therapeutic antibody development company Patrys (ASX: PAB) has been granted an Australian patent covering the use of its novel Deoxymab platform conjugated to nanoparticles (NP) for the targeted delivery of anti-cancer drugs. The patent is the first of its kind for the local market and covers the use of Deoxymab antibodies PAT-DX1 and PAT-DX3 with […]
Patrys’ lead drug candidate can cross blood brain barrier to target triple-negative breast cancers
A pre-clinical animal study by Australian therapeutic antibody company Patrys (ASX: PAB) has shown the development drug PAT-DX1-NP is able to cross the blood brain barrier and successfully target triple-negative breast cancer brain metastases. The Yale School of Medicine study found that PAT-DX1-NP administered by tail vein injection in a mouse model of triple-negative breast […]
Animal data shows potential for Patrys’ PAT-DX1 drug to help radiation fight aggressive brain tumours
Therapeutic antibody developer Patrys (ASX: PAB) has revealed new pre-clinical animal data that points to the potential for its lead candidate drug PAT-DX1 to improve survival rates for patients with highly aggressive forms of brain tumours. The company today released results from a newly completed study at the Yale School of Medicine, which involved using […]
Animal study shows Patrys’ breast cancer drug can suppress secondary tumours and complement radiation
A pre-clinical animal study using Patrys Limited’s (ASX: PAB) lead candidate drug PAT-DX1 has shown the drug can significantly suppress the growth of secondary brain tumours in patients with triple negative breast cancer (TNBC), even with a shortened dosing regimen. Brain tumours develop in up to 50% of patients with metastatic TNBC and can have […]
New results show Patrys’ PAT-DX1 drug could enhance survival rates in triple negative breast cancer patients
New pre-clinical data results released by therapeutic antibody developer Patrys Limited (ASX: PAB) have shown its new drug candidate PAT-DX1 has potential to increase survival rates in metastatic triple-negative breast cancer patients with secondary brain tumours. Ongoing testing of the drug is being done on mouse models of TNBC brain metastases by Dr James Hansen […]
Pre-clinical data from Patrys’ study with Yale confirms PAT-DX1 targets and kills brain cancer stem cells
Therapeutic antibody developer Patrys (ASX: PAB) has published a further round of pre‐clinical data for its drug candidates PAT-DX1 and PAT‐DX1‐NP – a humanized version of the 3E10 anti‐DNA antibody that aims to reduce cancerous brain tumours (glioblastomas). Dr James Hansen and Dr Jiangbing Zhou of the Yale School of Medicine have confirmed that PAT‐DX1 […]
Patrys winning greater recognition as pilot study leads to collaboration with Yale University
Therapeutic antibody developer Patrys (ASX: PAB) has said it has completed its pilot study into its drug candidate PAT-DX1, one of six different assets it has in development and currently at the pre-clinical stage. The pilot study showed that PAT‐DX1 has “antitumor activity” in an orthotopic, immune‐competent mouse model of triple negative breast cancer (TNBC), […]
Enhanced brain cancer survival rates shown in Patrys’ pre-clinical trials
Pre-clinical trials using Patrys’ (ASX: PAB) proprietary PAT-DX1 drug have revealed enhanced survival rates for animals suffering from ab aggressive form of brain cancer known as glioblastoma. Tissues from the human glioblastoma tumour were explanted onto mice, which were then treated with Patrys’ PAT-DX1 drug by tail vein injection. Mice that had received PAT-DX1 were […]
Patrys publishes upbeat pre-clinical data in the fight against brain cancer
Therapeutic antibody developer Patrys (ASX: PAB) has published additional pre‐clinical data for its drug candidate PATDX1, a humanized version of the 3E10 anti‐DNA antibody that aims to reduce cancerous brain tumours (glioblastomas). According to Patrys, research conducted by Dr James Hansen and Dr Jiangbing Zhou of Yale University have shown that “PAT‐DX1 administered by tail vein […]